Endothelin antagonism reduces hemoglobin A1c in patients with pulmonary hypertension.
Endothelin antagonism reduces hemoglobin A1c in patients with pulmonary hypertension.
复制标题
DOI：
10.1139/cjpp-2022-0132
复制
发表时间：
2022-08-01
影响因子：
2.1
通讯作者：
中科院分区：
文献类型：
--
作者：
我们的实验室最近报道了内皮素-1 （ET-1）受体的阻断可以减轻肥胖小鼠的胰岛素抵抗；因此，我们假设患者服用ET-1受体拮抗剂（ERAs）将改善血糖控制。密西西比大学医学中心（2013-2020）电子健康记录（EPIC）数据提取自≥18岁临床诊断为肺动脉高压（食品和药物管理局指征ERA使用）且2年内至少两次临床就诊的患者。接受era治疗的患者（n = 11）在年龄（61±14岁vs 60±14岁）、体重指数（BMI）（34±8 kg/m2 vs 35±11 kg/m2）、糖尿病患病率（73% vs 80%, p = 0.59）和随访时间（209±74天vs 283±180天）方面与未接受era治疗的患者（n = 137）相似。在随访中，ERA组（- 1.9±3 kg/m2）和对照组（- 1.6±5 kg/m2）的BMI下降幅度较小，但相似。在随访中，接受era治疗的患者的血红蛋白A1c （HbA1c）显著降低基线的- 12%±11%，而对照组患者没有出现这种情况（HbA1c升高2%±20%）。在整个人群中，基线HbA1c和ERA处方预测了HbA1c的下降，而与人口统计学、糖尿病患病率和糖尿病治疗没有显著关联。这些数据表明ET-1在促进胰岛素抵抗中的潜在作用，值得进一步研究使用这些药物来控制血糖。
Our lab recently reported that the blockade of endothelin-1 (ET-1) receptors attenuates insulin resistance in obese mice; therefore, we hypothesized that patients taking ET-1 receptor antagonists (ERAs) will have improved glycemic control. University of Mississippi Medical Center (2013–2020) electronic health record (EPIC) data were extracted from patients ≥18 years old with a clinical diagnosis of pulmonary hypertension (Food and Drug Administration indication for ERA use) and at least two clinical visits within 2 years. Patients prescribed ERAs (n = 11) were similar in age (61 ± 14 years vs. 60 ± 14 years), body mass index (BMI) (34 ± 8 kg/m 2 vs. 35 ± 11 kg/m2), diabetes prevalence (73% vs. 80%, p = 0.59), and follow-up time (209 ± 74 days vs. 283 ± 180 days) compared with patients not taking ERAs (n = 137). There was a small but similar decrease in BMI at follow-up in the ERA (−1.9 ± 3 kg/m2) and control patients (−1.6 ± 5 kg/m2). At follow-up, hemoglobin A1c (HbA1c) significantly decreased −12% ± 11% of baseline in patients taking ERAs, while this did not occur in the control patients (2% ± 20% increase in HbA1c). In the whole population, baseline HbA1c and ERA prescription predicted the fall in HbA1c, while there was no significant association with demographics, diabetes prevalence, and diabetic treatment. These data suggest a potential role of ET-1 in promoting insulin resistance and warrant further investigation into using these drugs for glycemic control.
登录
查看更多内容
影响因子：
3.7
作者：
Speed JS;George EM;Arany M;Cockrell K;Granger JP
通讯作者：
Granger JP
DOI：
10.1056/nejmsa2032271
发表时间：
2021-06-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Fang M;Wang D;Coresh J;Selvin E
通讯作者：
Selvin E
影响因子：
3.1
作者：
Jenkins, Haley N.;Williams, London J.;Speed, Joshua S.
通讯作者：
Speed, Joshua S.
影响因子：
8.3
作者：
Farrah, Tariq E.;Anand, Atul;Dhaun, Neeraj
通讯作者：
Dhaun, Neeraj
影响因子：
168.9
作者：
Heerspink, Hiddo J. L.;Parving, Hans-Henrik;de Zeeuw, Dick
通讯作者：
de Zeeuw, Dick